Phase IIa trial of PVT-100 in patients with vulnerable plaque who are to undergo carotid endarterectomy

Trial Profile

Phase IIa trial of PVT-100 in patients with vulnerable plaque who are to undergo carotid endarterectomy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms POMEGA
  • Sponsors Pivotal Therapeutics
  • Most Recent Events

    • 04 Jun 2015 According to a Pivotal Therapeutics media release, the trial entitled "Impact of an optimized Omega 3 formulation on the biochemical and histopathological composition of atheromatous plaques in patients to undergo carotid endarectomy" is sponsored by the University Hospital of Strasbourg and coordinated by interdisciplinary team of six vascular surgeons and twenty health professionals and monitored by the French health authorities via the national Clinical Trial Management System (CTMS).
    • 04 Jun 2015 According to a Pivotal Therapeutics media release, the company has enrol its first patient in the trial.
    • 04 Jun 2015 Status changed from planning to recruiting according to a Pivotal Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top